Clinical Trial Update: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pasireotide with or without everolimus in castration-resistant, chemotherapy-naive prostate cancer; the study is terminated with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Afinitor (everolimus)
• SIGNIFOR (PASIREOTIDE)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-01-16